 Carcinoma, Pancreatic Ductal
"Carcinoma, Pancreatic Ductal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Descriptor ID |
D021441
|
| MeSH Number(s) |
C04.557.470.200.025.232.750 C04.557.470.615.132.750 C04.588.274.761.750 C04.588.322.475.750 C06.301.761.750 C06.689.667.625 C19.344.421.750
|
| Concept/Terms |
Carcinoma, Pancreatic Ductal- Carcinoma, Pancreatic Ductal
- Carcinomas, Pancreatic Ductal
- Ductal Carcinoma, Pancreatic
- Ductal Carcinomas, Pancreatic
- Pancreatic Ductal Carcinomas
- Duct-Cell Carcinoma of the Pancreas
- Duct Cell Carcinoma of the Pancreas
- Pancreatic Ductal Carcinoma
- Ductal Carcinoma of the Pancreas
- Pancreatic Duct Cell Carcinoma
- Carcinoma, Ductal, Pancreatic
- Duct-Cell Carcinoma, Pancreas
- Carcinoma, Pancreas Duct-Cell
- Carcinomas, Pancreas Duct-Cell
- Duct Cell Carcinoma, Pancreas
- Duct-Cell Carcinomas, Pancreas
- Pancreas Duct-Cell Carcinoma
- Pancreas Duct-Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Pancreatic Ductal".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Ductal [C04.557.470.200.025.232]
- Carcinoma, Pancreatic Ductal [C04.557.470.200.025.232.750]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Ductal [C04.557.470.615.132]
- Carcinoma, Pancreatic Ductal [C04.557.470.615.132.750]
- Neoplasms by Site [C04.588]
- Digestive System Neoplasms [C04.588.274]
- Pancreatic Neoplasms [C04.588.274.761]
- Carcinoma, Pancreatic Ductal [C04.588.274.761.750]
- Endocrine Gland Neoplasms [C04.588.322]
- Pancreatic Neoplasms [C04.588.322.475]
- Carcinoma, Pancreatic Ductal [C04.588.322.475.750]
- Digestive System Diseases [C06]
- Digestive System Neoplasms [C06.301]
- Pancreatic Neoplasms [C06.301.761]
- Carcinoma, Pancreatic Ductal [C06.301.761.750]
- Pancreatic Diseases [C06.689]
- Pancreatic Neoplasms [C06.689.667]
- Carcinoma, Pancreatic Ductal [C06.689.667.625]
- Endocrine System Diseases [C19]
- Endocrine Gland Neoplasms [C19.344]
- Pancreatic Neoplasms [C19.344.421]
- Carcinoma, Pancreatic Ductal [C19.344.421.750]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Pancreatic Ductal".
This graph shows the total number of publications written about "Carcinoma, Pancreatic Ductal" by people in UAMS Profiles by year, and whether "Carcinoma, Pancreatic Ductal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 2 | 0 | 2 | | 2023 | 2 | 0 | 2 | | 2022 | 4 | 0 | 4 | | 2021 | 3 | 0 | 3 | | 2020 | 2 | 1 | 3 | | 2019 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2017 | 1 | 0 | 1 | | 2016 | 3 | 1 | 4 | | 2015 | 1 | 0 | 1 | | 2014 | 4 | 0 | 4 | | 2012 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Pancreatic Ductal" by people in Profiles over the past ten years.
-
Wolfe AR, Cui T, Baie S, Corrales-Guerrero S, Webb A, Castro-Aceituno V, Shyu DL, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Halloran M, Packard R, Robb R, Chen W, Denko N, Lisanti M, Thompson TC, Frank P, Williams TM. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Sci Adv. 2024 Mar; 10(9):eadj3551.
-
Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024; 15:1287459.
-
Wan L, Lin KT, Rahman MA, Ishigami Y, Wang Z, Jensen MA, Wilkinson JE, Park Y, Tuveson DA, Krainer AR. Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. Cancer Discov. 2023 07 07; 13(7):1678-1695.
-
Shah I, Silva-Santisteban A, Germansky KA, Trindade A, Raphael KL, Kushnir V, Pawa R, Mishra G, Anastasiou J, Inamdar S, Tharian B, Bilal M, Sawhney MS. Pancreatic Cancer Screening for At-Risk Individuals (Pancreas Scan Study): Yield, Harms, and Outcomes From a Prospective Multicenter Study. Am J Gastroenterol. 2023 09 01; 118(9):1664-1670.
-
Zhang W, Campbell DH, Walsh BJ, Packer NH, Liu D, Wang Y. Cancer-derived small extracellular vesicles: emerging biomarkers and therapies for pancreatic ductal adenocarcinoma diagnosis/prognosis and treatment. J Nanobiotechnology. 2022 Oct 14; 20(1):446.
-
de Andr?s MP, Jackson RJ, Felipe I, Zagorac S, Pilarsky C, Schlitter AM, Martinez de Villareal J, Jang GH, Costello E, Gallinger S, Ghaneh P, Greenhalf W, Kn?sel T, Palmer DH, Ruemmele P, Weichert W, Buechler M, Hackert T, Neoptolemos JP, Notta F, Malats N, Martinelli P, Real FX. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Gut. 2023 03; 72(3):535-548.
-
Zhang W, Wang L, Li D, Campbell DH, Walsh BJ, Packer NH, Dong Q, Wang E, Wang Y. Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study. Anal Methods. 2022 06 16; 14(23):2255-2265.
-
Schwartz I, Sharma P, Vankawala P, Cruz N, Abraham RR, Sussman DA, Girotra M. High Rate of Pancreatic Structural Changes Among Tobacco-Using Individuals at High Risk for Pancreatic Ductal Adenocarcinoma Undergoing Endoscopic Ultrasound. Pancreas. 2022 01 01; 51(1):e1-e3.
-
Zarei M, Shrestha R, Johnson S, Yu Z, Karki K, Vaziri-Gohar A, Epps J, Du H, Suva L, Zarei M, Safe S. Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma. Cancer Res Commun. 2021 11; 1(2):65-78.
-
Ramaker RC, Hardigan AA, Gordon ER, Wright CA, Myers RM, Cooper SJ. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition. BMC Cancer. 2021 May 29; 21(1):632.
-
Tsai PY, Lee MS, Jadhav U, Naqvi I, Madha S, Adler A, Mistry M, Naumenko S, Lewis CA, Hitchcock DS, Roberts FR, DelNero P, Hank T, Honselmann KC, Morales Oyarvide V, Mino-Kenudson M, Clish CB, Shivdasani RA, Kalaany NY. Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1. Proc Natl Acad Sci U S A. 2021 03 09; 118(10).
-
Mattila N, Hisada Y, Przybyla B, Posma J, Jouppila A, Haglund C, Sepp?nen H, Mackman N, Lassila R. Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-na?ve pancreatic cancer patients. Thromb Res. 2021 03; 199:21-31.
-
Vazzano J, Frankel WL, Wolfe AR, Williams TM, Chen W. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems. Hum Pathol. 2021 03; 109:1-11.
-
Wolfe AR, Robb R, Hegazi A, Abushahin L, Yang L, Shyu DL, Trevino JG, Cruz-Monserrate Z, Jacob JR, Palanichamy K, Chakravarti A, Williams TM. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clin Cancer Res. 2021 01 15; 27(2):554-565.
-
Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS. Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. J Surg Oncol. 2019 Dec; 120(7):1137-1141.
-
Thiruvengadam SS, Chuang J, Huang R, Girotra M, Park WG. Chronic pancreatitis changes in high-risk individuals for pancreatic ductal adenocarcinoma. Gastrointest Endosc. 2019 04; 89(4):842-851.e1.
-
Mattila N, Sepp?nen H, Mustonen H, Przybyla B, Haglund C, Lassila R. Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clin Appl Thromb Hemost. 2018 Nov; 24(8):1267-1275.
-
Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Cancer. 2017 Dec 01; 123(23):4680-4686.
-
Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, Orcutt S, Doepker MP, Gage K, Zhang G, Latifi K, Hoffe S, Jiang K, Coppola D, Centeno BA, Magliocco A, Li Q, Trevino J, Merchant N, Gillies R, Malafa M. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016 Dec 27; 7(52):85785-85797.
-
Beeghly-Fadiel A, Luu HN, Du L, Shi C, McGavic DP, Parikh AA, Raskin L. Early onset pancreatic malignancies: Clinical characteristics and survival associations. Int J Cancer. 2016 11 15; 139(10):2169-77.
-
Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, Bullock A, Gu X, Castan E, Zhang P, Najarian R, Muraru MS, Miksad R, Khosravi-Far R, Libermann TA. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Oncotarget. 2016 Apr 26; 7(17):23263-81.
-
Guo X, Hollander L, MacPherson D, Wang L, Velazquez H, Chang J, Safirstein R, Cha C, Gorelick F, Desir GV. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Sci Rep. 2016 Mar 14; 6:22996.
-
Krishna SG, Bhattacharya A, Ross WA, Ladha H, Porter K, Bhutani MS, Lee JH. Pretest prediction and diagnosis of metastatic lesions to the pancreas by endoscopic ultrasound-guided fine needle aspiration. J Gastroenterol Hepatol. 2015 Oct; 30(10):1552-60.
-
Giorgakis E, Mavroeidis V, Tsironis D, Davidson B. Vascular endothelial growth factor detection in serous pancreatic cysts: have we really reached a breakthrough? J Am Coll Surg. 2014 Sep; 219(3):591.
-
Malhotra N, Jackson SA, Freed LL, Styn MA, Sidawy MK, Haddad NG, Finkelstein SD. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. BMC Gastroenterol. 2014 Aug 01; 14:135.
-
Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014 May 06; 7(324):ra42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|